[{"address1": "9201 West Broadway Avenue", "address2": "Suite 650", "city": "Minneapolis", "state": "MN", "zip": "55445", "country": "United States", "phone": "763 416 2840", "fax": "763 416 2841", "website": "https://www.cvrx.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.", "fullTimeEmployees": 200, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kevin  Hykes", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 37057, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jared  Oasheim", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 576724, "exercisedValue": 0, "unexercisedValue": 3460054}, {"maxAge": 1, "name": "Mr. Paul  Verrastro", "age": 60, "title": "Chief Marketing & Strategy Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 598972, "exercisedValue": 0, "unexercisedValue": 2731936}, {"maxAge": 1, "name": "Mr. Paul  Pignato", "title": "Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jonelle R. Burnham", "age": 52, "title": "Vice President & General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer E. Englund", "title": "Senior Vice President of Global Clinical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip B. Adamson M.D., M.Sc.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.82, "open": 7.82, "dayLow": 7.02, "dayHigh": 8.03, "regularMarketPreviousClose": 7.82, "regularMarketOpen": 7.82, "regularMarketDayLow": 7.02, "regularMarketDayHigh": 8.03, "beta": 1.285, "forwardPE": -3.840206, "volume": 318802, "regularMarketVolume": 318802, "averageVolume": 219241, "averageVolume10days": 262830, "averageDailyVolume10Day": 262830, "bid": 7.41, "ask": 7.47, "bidSize": 100, "askSize": 200, "marketCap": 160887216, "fiftyTwoWeekLow": 7.02, "fiftyTwoWeekHigh": 33.135, "priceToSalesTrailing12Months": 3.8228204, "fiftyDayAverage": 14.0849, "twoHundredDayAverage": 18.6241, "currency": "USD", "enterpriseValue": 111373040, "profitMargins": -1.23583, "floatShares": 11644119, "sharesOutstanding": 21595600, "sharesShort": 870235, "sharesShortPriorMonth": 830797, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0403, "heldPercentInsiders": 0.09427, "heldPercentInstitutions": 0.79804003, "shortRatio": 7.67, "shortPercentOfFloat": 0.0661, "impliedSharesOutstanding": 23556300, "bookValue": 3.069, "priceToBook": 2.4275007, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -52011000, "trailingEps": -2.48, "forwardEps": -1.94, "enterpriseToRevenue": 2.646, "enterpriseToEbitda": -2.115, "52WeekChange": -0.3938161, "SandP52WeekChange": 0.26137078, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CVRX", "underlyingSymbol": "CVRX", "shortName": "CVRx, Inc.", "longName": "CVRx, Inc.", "firstTradeDateEpochUtc": 1625059800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "18e77560-d0bd-3e3c-99c4-c943c8d9d9cc", "messageBoardId": "finmb_1380491", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.45, "targetHighPrice": 23.0, "targetLowPrice": 14.0, "targetMeanPrice": 17.5, "targetMedianPrice": 16.5, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 80115000, "totalCashPerShare": 3.71, "ebitda": -52649000, "totalDebt": 30601000, "quickRatio": 10.551, "currentRatio": 12.184, "totalRevenue": 42086000, "debtToEquity": 46.183, "revenuePerShare": 2.015, "returnOnAssets": -0.29042, "returnOnEquity": -0.62700003, "freeCashflow": -24113500, "operatingCashflow": -39668000, "revenueGrowth": 0.35, "grossMargins": 0.84453005, "ebitdaMargins": -1.25099, "operatingMargins": -2.06425, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-26"}]